Madoka Kimura

1.7k total citations
44 papers, 1.1k citations indexed

About

Madoka Kimura is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Madoka Kimura has authored 44 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Madoka Kimura's work include Lung Cancer Treatments and Mutations (27 papers), Cancer Genomics and Diagnostics (11 papers) and Lung Cancer Research Studies (8 papers). Madoka Kimura is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Cancer Genomics and Diagnostics (11 papers) and Lung Cancer Research Studies (8 papers). Madoka Kimura collaborates with scholars based in Japan and Netherlands. Madoka Kimura's co-authors include Kazumi Nishino, Toru Kumagai, Fumio Imamura, Takako Inoue, Motohiro Tamiya, Toshiaki Takahashi, Junji Uchida, Nobuyuki Yamamoto, Kei Kunimasa and Tateaki Naito and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Madoka Kimura

42 papers receiving 1.0k citations

Peers

Madoka Kimura

PRM

ONCOL

PHYSI

Takaaki Tokito Japan

Luisa Carbognin Italy

Deepak Kilari United States

Atsushi Osoegawa Japan

Boris Duchemann France

Naoko Miura Japan

Filippos Koinis Greece

Tomoyoshi Takayama Japan

Keijiro Nozawa Japan

Emmanuelle Bourbouloux France

Takaaki Tokito Japan

Madoka Kimura

726 ×1.1

PRM

943 ×1.7

ONCOL

171 ×0.7

198 ×0.9

134 ×0.8

PHYSI

Citations per year, relative to Madoka Kimura Madoka Kimura (= 1×) peers Takaaki Tokito

Countries citing papers authored by Madoka Kimura

Since Specialization

Citations

This map shows the geographic impact of Madoka Kimura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Madoka Kimura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Madoka Kimura more than expected).

Fields of papers citing papers by Madoka Kimura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Madoka Kimura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Madoka Kimura. The network helps show where Madoka Kimura may publish in the future.

Co-authorship network of co-authors of Madoka Kimura

This figure shows the co-authorship network connecting the top 25 collaborators of Madoka Kimura. A scholar is included among the top collaborators of Madoka Kimura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Madoka Kimura. Madoka Kimura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kunimasa, Kei, Yosuke Hirotsu, Yoji Kukita, et al.. (2021). EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors. Cancer Genetics. 256-257. 131–135. 8 indexed citations

Kunimasa, Kei, Toru Oka, Makiko Oboshi, et al.. (2020). Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib. JACC CardioOncology. 2(1). 1–10. 58 indexed citations

Nishino, Kazumi, Kei Kunimasa, Madoka Kimura, et al.. (2020). Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report. BMC Pharmacology and Toxicology. 21(1). 26–26. 9 indexed citations

Tamiya, Motohiro, Akihiro Tamiya, Hidekazu Suzuki, et al.. (2019). Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?. Anticancer Research. 39(7). 3923–3929. 25 indexed citations

Kunimasa, Kei, Harumi Nakamura, Kazuko Sakai, et al.. (2019). Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. Lung Cancer. 132. 59–64. 18 indexed citations

Kimura, Madoka, et al.. (2019). Jasmonate production through chlorophyll a degradation by Stay-Green in Arabidopsis thaliana. Journal of Plant Physiology. 238. 53–62. 23 indexed citations

Kumagai, Toru, Yasuhiko Tomita, Shin‐ichi Nakatsuka, et al.. (2018). HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1. Thoracic Cancer. 9(4). 466–471. 9 indexed citations

Kunimasa, Kei, Kazumi Nishino, Madoka Kimura, et al.. (2018). Pembrolizumab-induced acute thrombosis. Medicine. 97(20). e10772–e10772. 40 indexed citations

Kunimasa, Kei, Taiki Isei, Harumi Nakamura, et al.. (2018). Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction. Investigational New Drugs. 36(6). 1138–1142. 12 indexed citations

10.

Inoue, Takako, Madoka Kimura, Junji Uchida, et al.. (2017). Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. International Journal of Clinical Oncology. 22(3). 600–604. 11 indexed citations

11.

Kimura, Madoka, Fumio Imamura, Takako Inoue, et al.. (2017). Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer. Molecular and Clinical Oncology. 7(1). 15–23. 2 indexed citations

12.

Inoue, Takako, Motohiro Tamiya, Akihiro Tamiya, et al.. (2017). Analysis of Early Death in Japanese Patients With Advanced Non–small-cell Lung Cancer Treated With Nivolumab. Clinical Lung Cancer. 19(2). e171–e176. 43 indexed citations

13.

Imamura, Fumio, Junji Uchida, Yoji Kukita, et al.. (2016). Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer. 94. 68–73. 64 indexed citations

14.

Kato, Kikuya, Junji Uchida, Yoji Kukita, et al.. (2016). Transient appearance of circulating tumor DNA associated with de novo treatment. Scientific Reports. 6(1). 38639–38639. 11 indexed citations

15.

Kimura, Madoka, Hiroko Endo, Takako Inoue, et al.. (2015). Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene. Journal of Thoracic Oncology. 10(3). 527–530. 23 indexed citations

16.

Akamatsu, Hiroaki, Yasuhiro Koh, Hirotsugu Kenmotsu, et al.. (2014). Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion. Journal of Thoracic Oncology. 9(7). 1048–1052. 28 indexed citations

17.

Kimura, Madoka, Tateaki Naito, Hirotsugu Kenmotsu, et al.. (2014). Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Supportive Care in Cancer. 23(6). 1699–1708. 137 indexed citations

18.

Murakami, Haruyasu, Hiroaki Akamatsu, Madoka Kimura, et al.. (2013). Differences in the efficacy of S‐1 monotherapy according to histological type in pretreated patients with advanced non‐small cell lung cancer. Thoracic Cancer. 5(2). 121–125. 1 indexed citations

19.

Imai, Hisao, Toshiaki Takahashi, Tetsuhiko Taira, et al.. (2013). Papillary Squamous Cell Carcinoma of the Trachea Associated with Human Papillomavirus-18 Infection. Internal Medicine. 52(24). 2785–2788. 1 indexed citations

20.

Kenmotsu, Hirotsugu, Tateaki Naito, Madoka Kimura, et al.. (2011). The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer. Journal of Thoracic Oncology. 6(7). 1242–1246. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact